Commercialization of a highly-sensitive, scalable and low-input compatible kit-based solution for discovery of translocations from ffpe tumor biopsies

Ended Project Grant Awarded Last action

Award ID
R44CA247185
Recipient
Awarding agency
Obligated
$10,050,119

Award facts

Assistance listing
93.396 Cancer Biology Research
Completion date
Originally
Funding
  • $9,050,846.00 Federal
  • $999,273.00 Non-federal
Place of performance
California, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $0 $0
Amendment $1,913,603 $0
Amendment $2,069,712 $0
Amendment Developing a kit-based research use only (RUO) translocation assay for deployment as a lab developed test (LDT) toward changing outcomes for patients with… $2,069,712 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $999,273 $0
Amendment $0 $0
Amendment $0 $0
Amendment $999,273 $999,273
Original award $999,273 $0
Show all 13

Quick answers

Who received award R44CA247185?

R44CA247185 was awarded to Arima Genomics, Inc. by National Cancer Institute (National Institutes of Health) on May 1, 2020.

How much is award R44CA247185 worth?

$10,050,119 has been obligated on R44CA247185: $9,050,846 in federal funding and $999,273 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award